High-performance system GreenLight laser: Indications and outcomes

Current Opinion in Urology

Volumn 19, Issue 1, 2009, Pages 33-37

  Van Cleynenbreugel, Ben ^a   Srirangam, Shalom J ^b   Van Poppel, Hendrik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; GreenLight laser; Lithium triborate; Photovaporization of the prostate; Potassium titanyl phosphate laser; Prostatectomy

Indexed keywords

ANTICOAGULANT AGENT;

COST EFFECTIVENESS ANALYSIS; HUMAN; LASER SURGERY; LOWER URINARY TRACT SYMPTOM; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SCORING SYSTEM; SURGICAL RISK; TREATMENT OUTCOME; VAPORIZATION;

HUMANS; LASER THERAPY; LENGTH OF STAY; MALE; PROSTATE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY CATHETERIZATION;

EID: 58149236870     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328317cab3     Document Type: Review

References (46)

1. Malek R, Kuntzman R, Barrett D. Photoselective potassium-titanyl- phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005; 174:1344-1348.
2. Bouchier D, Anderson P, Van Appledon S, et al. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006; 20:580-585.
3. Bachmann A, Ruszat R, Wyler S, et al. Photoselective vaporization of the prostate: the basal experience after 108 procedures. Eur Urol 2005; 47:798-804.
4. Te A, Malloy TR, Stein BS, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12 months results from the first United States multicenter prospective study. J Urol 2004; 172:1404-1408.
5. Sarica K, Alkan E, Luleci H, Tasci A. Photoselective vaporization of the enlarged prostate with KTP laser: long-term results in 240 patients. J Endourol 2005; 19:1199-1202.
6. Sandhu J, Ng C, Vanderbrink B, et al. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004; 64:1155-1159.
7. Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007; 51:1031-1038; discussion 1038-1041.
8. Woo H, Reich O, Backmann A, et al. Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with larger prostates (≥80ml). Eur Urol Suppl 2008; 7:378-383. An update on PVP in high-risk patient groups.
9. Wei J, Calhouan E, Jacobsen S. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2008; 179 (5 Suppl):S75-S80.
10. Van Exel N, Koopmanschap M, McDonnell J, et al. Medical consumption and costs during a one year follow up of patients with LUTS suggestive of BPH in six European Countries: report of the TRIUMPH study. Eur Urol 2006; 49:92-102.
11. Wilsom J, Urwin G, Stower M. The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. Ann R Coll Surg Engl 2004; 86:428-431.
12. Stafinski T, Menon D, Harris K, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Can Urol Assoc J 2008; 4:124-134. A cost analysis of PVP.
13. Reich O, Gratzke C, Stief C. Techniques and long-term results of surgical procedures for BPH. Eur Urol 2006; 49:970-978.
14. Borth C, Beiko D, Nickel J. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001; 57:1082-1085.
15. Borboroglu P, Kane C, Ward J, et al. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999; 162:1307-1310.
16. Mebust W, Holtgrewe H, Cocket A, et al. Transurethral prostatectomy: immediate and postoperative complications. A Co-operative study of 13 institutions involving 3885 patients. J Urol 1989; 141:243-247.
17. Flanigan R, Reda D, Wasson J, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160:12-16; discussion 16-17.
18. Horninger W, Unterlechner H, Strassr H, et al. Transurethral prostatectomy: mortality and morbidity. Prostate 1996; 28:195-200.
19. Reich O, Gratzke K, Backmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10 654 patients. J Urol 2008; 180:246-249.
20. Roos N, Wennberg J, Malenka D, et al. Mortality and re-operation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320:1120-1124.
21. Zlotta A, Djavan B. Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Curr Opin Urol 2002; 12:7-14.
22. Barber N, Muir G. High-power KTP laser prostatectomy: the new challenge to transurethral resection of the prostate. Curr Opin Urol 2004; 14: 21-25.
23. Anson K. Could the latest generation potassium titanyl phosphate lasers be the ones to make transurethral resection of the prostate an operation of historical interest only? Curr Opin Urol 2004; 14:27-29.
24. Muir G, Sancha F, Bachmann A, et al. Techniques and training with GreenLight HPS 120-W laser therapy of the prostate: position paper. Eur Urol Suppl 2008; 7:S370-S377. A description of the modular approach to PVP.
25. Malek R, Barrett D, Kuntzmann R. High power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 h later. Urology 1998; 51:254-256.
26. Hai M, Malek R. Photoselective vaporization of the prostate: initial experience with a new 80-W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 2003; 17:93-96.
27. Malek R, Kuntzmann R, Barrett D. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol 2000; 163:1730-1733.
28. Malek R, Kuntzmann R, Barrett D. KTP laser prostatectomy: long term experience. J Urol Suppl 2001; 165:369.
29. Sulser T, Reich O, Wyler S, et al. Photoselective KTP laser vaporization of the prostate: first experiences with 65 procedures. J Endourol 2004; 18:976-981.
30. Kumar S. Photoselective vaporization of the prostate: a volume reduction analysis in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia and carcinoma of the prostate. J Urol 2005; 173:511-513.
31. Volkan T, Ihsan T, Yilmaz O, et al. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate. Eur Urol 2005; 48:608-613.
32. Reich O, Bachmann A, Siebels M, et al. High power (80W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005; 173:158-160.
33. Fu WJ, Hong BF, Yang Y, et al. Photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia. Chin Med J (Engl) 2005; 118:1610-1614.
34. Jung G, Ok Y, Choi E. High-power KTP photoselective laser vaporization prostatectomy for treatment of benign prostatic hyperplasia [abstract]. Eur Assoc Urol Annu Meeting 2005.
35. Hamann M, Naumann C, Steif C, van der Horst C, Jünemann KP, Braun PM. Functional outcome following photoselective vaporisation of the prostate (PVP): urodynamic findings within 12 months follow-up. Eur Urol 2008; 54:902-910. Impact of PVP on urodynamic results, voiding function, quality of life and sexual function.
36. Pfitzenmaier J, Gilfrich C, Pritsch M, et al. Vaporization of prostates of ≥80 ml using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates <80 ml. BJU Int 2008; 102:322-327.
37. Horasanli K, Silay MS, Altay B, et al. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: a short-term prospective randomized trial. Urology 2008; 71:247-251.
38. Malek R. Photoselective potassium titanyl phosphate (KTP) laser vaporization of the prostate (PVP) vs transurethral resection of the prostate (TURP). Urology 2008; 72:718-719.
39. Alivizatos G, Skolarikos A, Chalikopoulos D, et al. Transurethral photoselecfive vaporization versus transvesical open enucleation for prostatic adenomas of more than 80 ml: 12-month results of a randomized prospective study. Eur Urol 2008; 54:427-437. A prospective study comparing PVP vs. open adenomectomy.
40. Dotan Z, Mor Y, Leibhovitch I, et al. The efficacy and safety of peri-operative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 2003; 168:610-613.
41. Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007; 52:1031-1041.
42. Yuan J, Wang H, Wu G, et al. High-power (80 W) potassium titanyl phosphate laser prostatectomy in 128 high-risk patients. Postgrad Med J 2008; 84: 46-49.
43. Sandhu J, Ng C, Gonzalez R, et al. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 2005; 19:1196-1198.
44. Bachman A, Schurch L, Ruzet R, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-center study of peri-operative morbidity and early functional outcome. Eur Urol 2005; 48:956-972.
45. Ruszat R, Wyler S, Seitz M, et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective nonrandomized two-centre study. BJU Int 2008 [Epub ahead of print].
46. Te AE. The next generation in laser treatments and the role of the GreenLight high performance system laser. Rev Urol 2006; 8:24-30.